S'abonner

A common single nucleotide polymorphism impairs B-cell activating factor receptor's multimerization, contributing to common variable immunodeficiency - 29/03/14

Doi : 10.1016/j.jaci.2013.11.021 
Kathrin Pieper, PhD a, b, Marta Rizzi, MD, PhD a, , Matthaios Speletas, MD, PhD c, , Cristian R. Smulski, PhD d, , Heiko Sic, PhD a, b, Helene Kraus, MSc a, b, Ulrich Salzer, MD a, Gina J. Fiala, MSc a, e, Wolfgang W. Schamel, PhD a, e, Vassilios Lougaris, MD f, Alessandro Plebani, MD f, Lennart Hammarstrom, MD, PhD g, Mike Recher, MD h, Anastasios E. Germenis, MD, PhD c, Bodo Grimbacher, MD a, Klaus Warnatz, MD, PhD a, Antonius G. Rolink, PhD i, Pascal Schneider, PhD d, Luigi D. Notarangelo, MD i, Hermann Eibel, PhD a
a Centre for Chronic Immunodeficiency, University Medical Centre Freiburg, Freiburg, Germany 
b Faculty of Biology, Albert-Ludwigs-University, Freiburg, Germany 
c Faculty of Medicine, Department of Immunology & Histocompatibility, University of Thessaly, Larissa, Greece 
d Faculty of Medicine, Department of Biochemistry, University of Lausanne, Lausanne, Switzerland 
e Faculty of Biology, Institute of Biology III, and BIOSS Center for Biological Signalling Studies, Albert-Ludwigs University Freiburg, Freiburg, Germany 
f Pediatric Clinic and A. Nocivelli Institute of Molecular Medicine, University of Brescia, Spedali Civili, Brescia, Italy 
g Department of Laboratory Medicine, Karolinska Institutet, Huddinge, Sweden 
h Division of Immunology and The Manton Center for Orphan Disease Research Center, Children's Hospital, Boston, Mass 
i Developmental and Molecular Immunology, Department of Biomedicine, University of Basel, Basel, Switzerland 


 This work was supported by the German Cancer Research Fund (grant no. 108935 to H.E. and K.P.), the European Union 7th framework grant (no. HEALTH-F2-2008-201549 to H.E., B.G., U.S., L.H., V.L., and A.P.), the Federal Ministry of Education and Research (grant no. BMBF 01 E0 08 03 to M. Rizzi), the Swiss National Science Foundation (grant no. PASMP3-127678/1 to M. Recher and grant no. 31003A_138065 to P.S.), Merck-Serono (to P.S.), and the Deutsche-Forschungsgemeinschaft (grant no. TRR130 TP06 to H.E., grant no. EXC294 to W.W.S., and SFB620 project C7 to U.S.).
 Disclosure of potential conflict of interest: M. Speletas is employed by the University of Thessaly; has received research support from General Secretariat of Research; has received lecture fees from Amgen Hellas for immunology lectures; and has received travel fees from Shire Hellas, Behring Hellas, and Bristol-Meyer Hellas. L. Hammarstrom has received research support from the Swedish Research Council. M. Recher has received research support from the Swiss National Science Foundation and the University of Basel, Switzerland. A. E. Germenis has received consultant fees from Novartis and Shire, is employed by the University of Thessaly, has received lecture fees from Amgen and Novartis, and has received travel fees from Shire. B. Grimbacher has received research support from University College London (UCL) (FP7 Eu Grant [EURO-PADnet Health-F2-2008-201549]) and Uniklinik Freiburg (BMBF 01 Eo0803); is employed by UCL; receives royalties from Springer; and has received travel fees from CSL Behring, the American Academy of Allergy, Asthma & Immunology, Japanese Society of Immunodeficiency, European Society of Immunodeficiency, Latin American Society of Immunodeficiency, Primary Immunodeficiency Meeting. K. Warnatz has received research support and travel support from EURPADnet EU-FP7; has received lecture fees and honoraria from Baxter, GlaxoSmithKline, CSL Behring, Pfizer, the American Academy of Allergy, Asthma & Immunology, Biotest, and Novartis Pharma; is employed by a CCI grant from Bundesministerium für Bildung und Forschung; has research support pending from Deutsche Forschungsgesellschaft; and has received fees for manuscript preparation from UCB Pharma. P. Schneider has received research support from Merck-Serono and Edimer Pharmaceuticals and receives royalties from Adipogen. L. D. Notarangelo is a board member for a program in Molecular and Cellular Medicine, the Pediatric University Hospital “meyer,” and the Board of Scientific Counselors, the National Institues of Allergy and Infectious Diseases, and the National Institutes of Health (NIH); is employed by Boston Children's Hospital; has received research support from the NIH and March of Dimes; and receives royalties from UpToDate. H. Eibel has received research support from the German Cancer Research Fund and Deutsche Forschungsgemeinschaft. The rest of the authors declare that they have no relevant conflicts of interest.


© 2013  American Academy of Allergy, Asthma & Immunology. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 133 - N° 4

P. 1222 - avril 2014 Retour au numéro
Article précédent Article précédent
  • Nasopharyngeal Proteobacteria are associated with viral etiology and acute wheezing in children with severe bronchiolitis
  • Embriette R. Hyde, Joseph F. Petrosino, Pedro A. Piedra, Carlos A. Camargo, Janice A. Espinola, Jonathan M. Mansbach
| Article suivant Article suivant
  • Vaccine strain varicella-zoster virus–induced central nervous system vasculopathy as the presenting feature of DOCK8 deficiency
  • Angela Sabry, Pia J. Hauk, Huie Jing, Helen C. Su, Nicholas V. Stence, David M. Mirsky, Maria A. Nagel, Jordan K. Abbott, Leonard L. Dragone, Jennifer Armstrong-Wells, Donna J. Curtis, Randall Cohrs, D. Scott Schmid, Don Gilden, Erwin W. Gelfand

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Elsevier s'engage à rendre ses eBooks accessibles et à se conformer aux lois applicables. Compte tenu de notre vaste bibliothèque de titres, il existe des cas où rendre un livre électronique entièrement accessible présente des défis uniques et l'inclusion de fonctionnalités complètes pourrait transformer sa nature au point de ne plus servir son objectif principal ou d'entraîner un fardeau disproportionné pour l'éditeur. Par conséquent, l'accessibilité de cet eBook peut être limitée. Voir plus

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2026 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.